Literature DB >> 28258743

Loco-regional treatment of HCC: current status.

L Crocetti1, I Bargellini2, R Cioni2.   

Abstract

Hepatocellular carcinoma (HCC) represents one of the few cancers for which locoregional treatments are recognised as being able to cure and/or prolong survival and are included in international guidelines. This is due to the unique nature of HCC, in most cases occurring in patients with underlying virus- or alcohol-related cirrhosis. The treatment choice in patients with HCC is therefore driven not only by tumour staging, as in the great majority of cancers, but also by careful evaluation of liver function and physical status. Another specific feature of HCC is that it is the only tumour that can be cured by organ transplantation, with the aim of treating both the cancer and underlying liver disease. These characteristics configure a complex scenario and prompt the need for close cooperation among interventional oncologists, surgeons, hepatologists, and anaesthesiologists. In patients with limited hepatic disease, preserved hepatic function and good performance status, categorised as very early and early-stage HCC according to the Barcelona Clinic Liver Cancer (BCLC) classification, image-guided tumour ablation is included among the curative treatments. More than half of patients with HCC are, however, diagnosed late, despite the widespread implementation of surveillance programmes, when curative treatments cannot be applied. For patients presenting with multinodular HCC and relatively preserved liver function, absence of cancer-related symptoms, and no evidence of vascular invasion or extrahepatic spread transcatheter arterial chemoembolisation (TACE) is the current standard of care. Although anti-tumour activity and promising survival results has been reported in cohorts of patients with advanced HCC treated with radio-embolisation, systemic treatment with the multi-kinase inhibitor, sorafenib, is still recommended for patients at this stage. In this article, current treatment strategies for HCC according to tumour stage are discussed, underlining the latest advances in the literature and technical developments.
Copyright © 2017 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28258743     DOI: 10.1016/j.crad.2017.01.013

Source DB:  PubMed          Journal:  Clin Radiol        ISSN: 0009-9260            Impact factor:   2.350


  22 in total

1.  Prognostic Significance of Treatment Strategies for the Recurrent Hepatocellular Carcinomas After Radical Resection.

Authors:  Ryo Saito; Hidetake Amemiya; Naohiro Hosomura; Hiromichi Kawaida; Suguru Maruyama; Hiroki Shimizu; Shinji Furuya; Hidenori Akaike; Yoshihiko Kawaguchi; Makoto Sudo; Shingo Inoue; Hiroshi Kono; Daiduke Ichikawa
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

2.  Modification of the method to establish a hepatic VX2 carcinoma model in rabbits.

Authors:  Huan Tong; Li-Geng Duan; Hong-Ying Zhou; Shi Feng
Journal:  Oncol Lett       Date:  2018-02-07       Impact factor: 2.967

3.  The (Eternal) Debate on Microwave Ablation Versus Radiofrequency Ablation in BCLC-A Hepatocellular Carcinoma.

Authors:  Angela Dalia Ricci; Alessandro Rizzo; Chiara Bonucci; Simona Tavolari; Andrea Palloni; Giorgio Frega; Veronica Mollica; Nastassja Tober; Elena Mazzotta; Cristina Felicani; Carla Serra; Giovanni Brandi
Journal:  In Vivo       Date:  2020 Nov-Dec       Impact factor: 2.155

Review 4.  Neoantigen Specific T Cells Derived From T Cell-Derived Induced Pluripotent Stem Cells for the Treatment of Hepatocellular Carcinoma: Potential and Challenges.

Authors:  Fei Lu; Xiao-Jing-Nan Ma; Wei-Lin Jin; Yang Luo; Xun Li
Journal:  Front Immunol       Date:  2021-05-13       Impact factor: 7.561

5.  Initial experience of anti-PD1 therapy with nivolumab in advanced hepatocellular carcinoma.

Authors:  Duan Feng; Xie Hui; Lu Shi-Chun; Bai Yan-Hua; Cui Li; Li Xiao-Hui; Yan Jie-Yu
Journal:  Oncotarget       Date:  2017-08-08

6.  Extrahepatic metastasis of hepatocellular carcinoma to the paravertebral muscle: A case report.

Authors:  Kazuhiro Takahashi; Krishna G Putchakayala; Mohamed Safwan; Dean Y Kim
Journal:  World J Hepatol       Date:  2017-08-08

7.  Low levels of tumor suppressor candidate 3 predict poor prognosis of patients with hepatocellular carcinoma.

Authors:  Xu-Ren Sheng; Song-Ge Xing; Run-Dong Wang; Kang Chen; Wei-Dong Jia
Journal:  Onco Targets Ther       Date:  2018-02-21       Impact factor: 4.147

8.  Safety and efficacy of percutaneous microwave ablation for post-procedural haemostasis: a bi-central retrospective study focusing on safety and efficacy.

Authors:  Tian'an Jiang; Alexis Kelekis; Qiyu Zhao; Argyro Mazioti; Jia Liu; Nikolaos Kelekis; Guo Tian; Dimitrios Filippiadis
Journal:  Br J Radiol       Date:  2019-12-12       Impact factor: 3.039

9.  Comparison of transcatheter arterial chemoembolization with raltitrexed plus liposomal doxorubicin vs. tegafur plus pirarubicin for unresectable hepatocellular carcinoma.

Authors:  Rui Liao; Xing-Diao Zhang; Gui-Zhong Li; Ke-Le Qin; Xiong Yan
Journal:  J Gastrointest Oncol       Date:  2020-08

10.  A case report of remarkable response to association of radiofrequency ablation with subsequent Atezolizumab in stage IV nonsmall cell lung cancer.

Authors:  Jie Yin; Jingyin Dong; Wei Gao; Yina Wang
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.